A multi-center, open-label, single-arm, Phase 3b study of macitentan in patients with Pulmonary Arterial Hypertension to psychometrically validate the PAH-SYMPACT instrument
Purpose of this study is:
1)To evaluate a questionnaire called the PAH-SYMPACT, to understand if it can measure quality of life in patients with pulmonary arterial hypertension.
2)To evaluate the validity and reliability of the questionnaire PAH-SYMPAC.
3)To find out more about the safety of the study drug for pulmonary arterial hypertension
4)To explore the effects of study drug on PAH symptoms and their impact in patients with PAH.
Pulmonary Arterial Hypertension
Men and women between ages 18-80 with symptomatic Pulmonary Arterial Hypertension
18 - 80
Healthy Volunteers Needed
Duration of Participation
approximately 20 months
Actelion Pharmaceuticals US, Inc.
5000 Shoreline Court
South San Francisco, CA 94080
Upto $200 will be paid for travel expenses, based on expense receipts.